News
-
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K. - Biocon
This first generic Liraglutide approval in a major regulated market strengthens Biocon’s leadership in complex drug products and future growth drivers for the generics business
넶4 2025-04-23 -
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist - BioSpace
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and
넶26 2025-03-25 -
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial
Trial continues as planned to 52 weeks to further characterise the risk-benefit profile
넶20 2025-03-18
Better Health with ALVANTIS Peptide
Facilities
Contact
Shenzhen Alvantis Pharma Co., Ltd.
Address: Room 1902, Building D3, Nanshan Wisdom Park, No.1001, Xueyuan Avenue, Nanshan District, Shenzhen
E-mail:info@xinspharma.com
Products
